CI The Cigna Group

The Cigna Group is a diversified global health services organization offering pharmacy benefit management (Evernorth), commercial health insurance, and international health coverage. Sector: Healthcare.

The Cigna Group (CI) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Examining the company through a capital allocation lens, ROIC is 9.81%, WACC is 5.37%, and the economic spread is 4.45%. On balance, the company is generating returns above their cost of capital, though the margin is slim enough to warrant attention. Supporting metrics show ROE at 14.83% and ROA at 3.97%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that is value-creative but with less room for execution slippage.

Multiple analysis puts the company at trailing P/E of 12.17, forward P/E of 8.90, PEG of 4.50. Trailing and forward multiples are nearly identical, indicating the market is pricing the company on a relatively static earnings assumption. Growth-adjusted, the company is priced at a premium — a level that demands consistent execution and limits the potential for multiple expansion from here. The aggregate current ratio of 0.85 reflects tighter near-term liquidity — a factor worth monitoring if macro conditions tighten. The combined valuation and liquidity profile points to a company where current prices embed meaningful growth expectations, and where delivery against those expectations will drive the return outcome.

From gross to free cash flow, gross margin sits at 9.30%, operating margin at 2.24%, and free cash flow margin at 3.06%. At this level, gross margins signal that pricing power is constrained and direct cost management is a key performance driver. At this level, operating margins signal that earnings quality is limited — a feature of growth-stage or restructuring businesses. The company's FCF margin signals that most revenue is being consumed before reaching the free cash flow line — a feature of early-stage or heavily invested businesses. The margin profile is mixed, with some layers more resilient than others and less room for execution slippage.

Revenue momentum and analyst targets together paint a picture where the estimated 12-month price change of 29.40%, where consensus expectations favor gradual appreciation over the next year, while TTM revenue growth of 10.39% reflecting moderate but reliable revenue progress across the company. Reported revenue growth is the operational foundation; the analyst target spread shows what the market is willing to pay above it — and that premium can evaporate quickly if delivery slips. For investors, the central question is whether the operating momentum visible in revenues is durable enough to support the price appreciation implied by consensus targets. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The fundamental case holds up across most key dimensions — the combination of positive economic spread, reasonable valuation, and analyst support is constructive.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.